The global cell line development market size was US$ 5886.08 million in 2021. The global cell line development market size is forecast to reach US$ 15,678.3 million by 2030, growing at a compound annual growth rate (CAGR) of 11.5% during the forecast period from 2022 to 2030.
Cellular machinery takes over during the process of cell line development in order to create therapeutic biological agents and other relevant proteins. Furthermore, the manufacture of biotherapeutic items, including bispecific monoclonal antibodies, monoclonal antibodies, fusion proteins, and vaccines, depends heavily on the establishment of stable and high-production cell lines. Bacterial, yeast, plant, and mammalian expression systems can all utilize to create new cell lines. These cell lines can also utilize for screening, large-scale chemical synthesis, and research on medication development.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The COVID-19 pandemic had a negative impact on the global market. All stages of drug development were affected by the COVID-19 pandemic, which also forced numerous pharmaceutical firms and clinical research organizations (CROs) to halt their clinical investigations. Researchers undertaking continuing studies encounter a number of major hurdles, including stay-at-home directives, social distance standards, and pervasive worry.
Regional Analysis
North America accounted for a major market share in 2021 and is forecast to remain dominant during the forecast period. As a result of the well-established developed healthcare infrastructure and services and rising government initiatives. In addition, execution of innovative technologies, acceleration of research in the biopharmaceutical and biotechnology sectors, the existence of key market players, and favorable initiatives undertaken by the governments. Thus, these factors boost the market growth in the region.
Leading Competitors
The leading prominent companies profiled in the global cell line development market are:
Scope of the Report
The global cell line development market segmentation focuses on Product, Source, Type of Cell Line, Application, and Region.
Segmentation based on Product
Segmentation based on Source
Segmentation based on Type of Cell Line
Segmentation based on Application
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL CELL LINE DEVELOPMENT MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL CELL LINE DEVELOPMENT MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 REAGENTS & MEDIA
5.3 EQUIPMENT
5.3.1 INCUBATOR
5.3.2 CENTRIFUGE
5.3.3 BIOREACTOR
5.3.4 STORAGE EQUIPMENT
5.3.5 MICROSCOPE
5.3.6 ELECTROPORATORS
5.3.7 FACS
5.3.8 OTHERS
5.4 ACCESSORIES & CONSUMABLE
6 GLOBAL CELL LINE DEVELOPMENT MARKET, BY SOURCE
6.1 OVERVIEW
6.2 MAMMALIAN
6.3 NON-MAMMALIAN
6.3.1 INSECTS
6.3.2 AMPHIBIANS
7 GLOBAL CELL LINE DEVELOPMENT MARKET, BY TYPE OF CELL LINE
7.1 OVERVIEW
7.2 RECOMBINANT
7.3 HYBRIDOMAS
7.4 CONTINUOUS CELL LINE
7.5 PRIMARY CELL LINE
8 GLOBAL CELL LINE DEVELOPMENT MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DRUG DISCOVERY
8.3 TOXICITY TESTING
8.4 BIOPRODUCTION
8.5 TISSUE ENGINEERING
8.6 RESEARCH
9 GLOBAL CELL LINE DEVELOPMENT MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL CELL LINE DEVELOPMENT MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
11 COMPANY PROFILES
11.1 SIGMA-ALDRICH CORP.
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.2 LONZA GROUP AG
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.3 CORNING INC.
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.4 EUROFINS
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.5 GE HEALTHCARE
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.6 GENSCRIPT BIOTECH CORPORATION
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.7 SYNGENE INTERNATIONAL LIMITED
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.8. NOVARTIS
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.9 SAMSUNG BIOLOGICS
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.10 HORIZON DISCOVERY
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.11 THERMO FISHER SCIENTIFIC INCORPORATED
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.12 WUXI APPTEC.
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved